Valuation: Theravance Inc

Market Cap 1.48B 1.32B 1.23B 1.12B 2.11B 142B 2.13B 14.86B 5.76B 72.78B 5.56B 5.44B 234B P/E 2026 *
9.18x
P/E 2027 * 9.06x
Enterprise Value 955M 849M 792M 722M 1.36B 91.82B 1.37B 9.58B 3.71B 46.94B 3.59B 3.51B 151B EV / Sales 2026 *
2.12x
EV / Sales 2027 * 1.57x
Free-Float
98.99%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 42 2020-05-19
Director of Finance/CFO 60 2023-08-20
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 75 2018-02-11
Director/Board Member 66 2018-02-11
Director/Board Member 42 2025-05-18
Change 5-day change 1-year change 3-year change Capi.($)
-0.61%-3.43%+39.40%+112.31% 1,019B
-1.02%-5.60%+37.67%+65.02% 617B
+1.11%-0.58%+11.10%+77.28% 464B
+0.34%-3.01%+61.21%+40.71% 356B
-0.95%-4.05%+21.60%+39.37% 333B
-1.46%-2.89%+11.84%+24.60% 267B
-1.35%-5.43%-4.69%+8.40% 244B
-1.04%-2.79%+35.52%+51.34% 218B
-1.87%-4.10%+30.92%+95.33% 179B
Average -0.23%-3.39%+27.17%+57.15% 410.8B
Weighted average by Cap. +0.42%-3.33%+30.52%+68.96%

Financials

2026 *2027 *
Net sales 451M 401M 374M 341M 643M 43.38B 649M 4.53B 1.75B 22.18B 1.69B 1.66B 71.18B 490M 435M 406M 370M 699M 47.11B 705M 4.92B 1.91B 24.08B 1.84B 1.8B 77.29B
Net income 179M 159M 149M 135M 255M 17.23B 258M 1.8B 697M 8.81B 673M 658M 28.26B 175M 155M 145M 132M 249M 16.78B 251M 1.75B 679M 8.58B 655M 641M 27.53B
Net Debt -526M -467M -436M -398M -750M -50.56B -757M -5.28B -2.05B -25.85B -1.97B -1.93B -82.95B -712M -633M -590M -538M -1.01B -68.44B -1.02B -7.14B -2.77B -34.99B -2.67B -2.62B -112B
Logo Theravance Inc
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. Its royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, it is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. Its products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO, is for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in a Phase III clinical trial.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-